Effectiveness of neoadjuvant chemotherapy with FOLFOX7 in advanced gastric cancer

ZHANG   Li; LI  Xiang-Yang; LU   Xiang; ZHANG   Qing

PDF(581 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2012, Vol. 23 ›› Issue (12) : 1072-1074.

Effectiveness of neoadjuvant chemotherapy with FOLFOX7 in advanced gastric cancer

ZHANG Li¹,LI Xiangyang¹,LU Xiang¹,ZHANG Qing²

Author information +

History +

Abstract

Objective To evaluate the efficacy and toxicity of neoadjuvant chemotherapy with FOLFOX7 in the treatment of advanced gastric cancer. Methods Sixty-six patients with advanced gastric cancer were enrolled and were randomized to groups treated with or without neoadjuvant chemotherapy before operation (n=33/group). Preoperative chemotherapy with two cycles of FOLFOX7 were administered. The response in the primary tumor, resection rate and the chemotherapy toxicity were observed after neoadjuvant chemotherapy with FOLFOX7. Results The overall resection rate and radical resection rate in the operation with neoadjuvant chemotherapy group (93.9% and 57.6％) were higher than those in the operation without neoadjuvant chemotherapy group (78.8％and 36.4％). There were significant differences in the overall resection rate and radical resection rate between the two groups (χ²=3.911，P=0.048 and χ²=4.234，P=0.0394 ), while no significant change in complication incidence rate between the two groups. Histopathogical responses were evaluated as mild，moderate and marked in 3，4 and l cases, respectively．Conclusions FOLFOX7 is an effective and well-tolerated medicament as neoadjvant chemotherapy for the patients with advanced gastric cancer.

Key words

advanced gastric cancer / neoadjuvant chemotherapy / surgery

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

ZHANG Li,LI Xiangyang,LU Xiang,ZHANG Qing. Effectiveness of neoadjuvant chemotherapy with FOLFOX7 in advanced gastric cancer[J]. Medical Journal of the Chinese People Armed Police Forces. 2012, 23(12): 1072-1074

References

［1］ Mezhir J J, Tang L H, Coit D G. Neoadjuvant therapy of locally advanced gastric cancer ［J］. Surg Oncol, 2010，101(4):305-314.
［2］杨喆，王治国.多西他赛联合顺铂、氟尿嘧啶和亚叶酸的新辅助化疗方案治疗不能切除进展期胃癌的疗效观察［J］.中国癌症杂志，2006，16（5）：346-350.
［3］ Trotti A, Bentzen S M. The need for adverse effects reporting standards in oncology clinical trials［J］. J Clin Oncol , 2004, 22(1):19-22.
［4］盛贤能，韩晓鹏，李文惠，等.进展期胃癌新辅助化疗的现状与进展［J］.中国综合临床,2010，26（4）：444-446.
［5］ Frei E. Clinical cancer research: an embattled species［J］. Cancer,1982, 50: 1979-1992.
［6］ Wilke H, Prensser P, Fink U, et al．Preoperative chemotherapy in locally advanced and nonresectable gastric cancer：a phase II study with etoposide，doxorubicin，and cisplatin［J］．J Clin Oncol, 1989, 7(9)：1318-1326．
［7］ Cunningham D, Allum W H, Stenning S P,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cance［J］.N Engl J Med, 2006, 355(1):11-20.
［8］ Ng K, Meyerhardt J A, Fuchs C S. Adjuvant and neoadjuvant approaches in gastric cancer［J］.Cancer J, 2007,13(3):168-174.
［9］ Sym S J, Chang H M, Ryu M H, et al. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer［J］. Ann Surg Oncol,2010,17(4):1024-1032.
［10］ Becker K，Mueller J D，Schulmacher C，et a1．Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy［J］．Cancer，2003，98(7)：1521-1530.
［11］ Lasser P, Rougier P, Mahjoubi M, et al. Neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma［J］. Chirurgie, 1989, 115: 365-372.
［12］ Kato M, Kinoshita K, Sawa T, et al. Neoadjuvant chemotherapy of far advanced gastric cancer--effect of preoperative chemotherapy by PMUE (CDDP, MMC, UFT,etoposide) ［J］. Gan To Kagaku Ryoho,1990,17: 391-396.
［13］ Chung H C, Roh J K, Park Y J, et al. Locally advanced unresectable gastric cancer successfully resected after neoadjuvant chemotherapy with FADE regimen［J］.Yonsei Med J ,1990, 31: 74-79.
［14］金懋林.进展期胃癌全身化学治疗研究新进展［J］.癌症进展杂志，2007 , 5(1):18-24.
［15］ Kinoshita K，Yonemura Y，Sawa T．5-fluorouracil，methotrexate，leucovorin，CDDP and epirnbicin (FEPMTX)：a wide-spectrum regimen ot salvage chemotherapy for high grade advanced gastric cancer［J］．Hepatogastroenterology，2003，50(53)：1716-1719．[ZK)]
(2012-07-25